Precision nanosystems

Precision Nanosystems

Expertise Partner

Precision NanoSystems Inc. (PNI) is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI’s NanoAssemblr® microfluidic instruments, GenVoy™
lipid nanoparticle delivery reagents, and Biopharmaceutical Services enable researchers to translate disease biology insights into non-viral genomic medicines.


Micropore Technologies

Event Partner 

Micropore’s range of advanced crossflow equipment is a unique system that utilises consistent physics, mechanism, conditions and geometry across a range of devices enabling development using a micro device with 100,000 pores delivering as little as 1ml which can be simply accelerated to deliver 20 litres of formulation per hour. And the micro device configuration is seamless transferable to industrial scale units with 10 million pores capable of outputting outputs of 1500 litres per hour.



Exhibition Partner 

Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake lifesaving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

Beacon lg

Beacon Intelligence

Clinical Trial Partner

Cancer vaccines have re-emerged as a promising therapeutic option. Advancements in personalized approaches, delivery systems and antigen selection platforms present new opportunities for the development of effective cancer vaccines. The recent potential seen in mRNA-based vaccines has only added to this. Beacon Cancer Vaccine covers trial and drug records for clinical, preclinical, approved and discontinued prophylactic and therapeutic cancer vaccines.